Below is the list of confirmed international speakers for NDLR 2022.
To view national speakers. click here.
Daniel G. Tenen (Singapore)
Professor Tenen is a leader in gene regulation in both normal differentiation and cancer, with a focus on leukemia, lung cancer, and liver cancer. Current efforts include basic studies understanding gene regulation in normal and leukemic hematopoietic stem cells, with an aim to develop novel ways of manipulating gene expression in stem cells as well as exploiting differences between normal and leukemic stem cells as a basis for targeted leukemia stem cell therapy, and the role of stem cell oncofetal proteins in leukemia and solid tumors, especially liver cancer.
Dr Ann Mullally (USA)
Dr. Ann Mullally is an Associate Professor of Medicine at Harvard Medical School and a physician-scientist at Brigham and Women’s Hospital (BWH). She holds a weekly clinic for patients with myeloproliferative neoplasms (MPN) at Dana-Farber Cancer Institute (DFCI) and runs a research laboratory focused on myeloid malignancies, primarily MPN. Her clinical interests include early intervention strategies to target disease-propagating MPN stem cells and the development of immunological approaches to target mutant calreticulin (CALR) in MPN. Her laboratory studies the genetics, biology and therapy of MPN using primary patient samples, mouse models and multiple in vitro model systems. Dr. Mullally’s laboratory research interests include the biology of mutant CALR and JAK2V617F in MPN, the biology of myelofibrosis, MPN stem cells and the development of novel therapeutic strategies to preferentially target them. The overarching goal of her research is to advance the understanding of the biology of MPN and to translate this into improved treatment options for patients dealing with these diseases.
Dr Robert Weinkove (New Zealand)
Dr Weinkove leads the Malaghan Institute’s clinical CAR T-cell programme. His research interests include cancer immunotherapy, B-cell malignancies, and haemato-oncology supportive care. He studied medicine at the University of Cambridge and Kings College London, trained in General Medicine and Haematology at Guy’s and St Thomas’ Hospitals in London and the Medizinische Hochschule Hannover in Germany, and completed an Immunology PhD with the University of Otago.
Dr Ravindra Majeti (USA)
Ravi Majeti MD, PhD is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies.. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >90 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award. Dr. Majeti is currently a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and serves of the editorial boards of Blood and eLife.
Dr Ilaria Iacobucci (USA)
Ilaria Iacobucci, PhD, is a Staff Scientist in Dr. Charles Mullighan laboratory in the Department of Pathology at St. Jude Children’s Research Hospital, Memphis (USA). Her research focuses on the understanding of mechanisms underlying the pathogenesis of high-risk myeloid and lymphoid leukemia subtypes in both children and adults through the identification of novel genetic alterations with a diagnostic, prognostic and therapeutic relevance and the development of preclinical in vitro and in vivo models which faithfully recapitulate human leukemia. She has published >120 peer-reviewed articles and contributed to the identification of multiple new subtypes of acute lymphoblastic leukemia (ALL), such as EPOR-rearranged, DUX4/ERG-deregulated, and MEF2D-rearranged and PAX5P80R ALL. She has defined the genomic landscape of acute erythroid leukemia (AEL) and identified multiple subgroups with distinct genomic features and transcriptional profiles and generated a number of new engineered mouse models of lymphoid, erythroid and myeloid leukemia that faithfully recapitulate the genetic alterations observed in human diseases and that have allowed mechanistic and preclinical studies. She is a recipient of many international awards, including American Association for Cancer Research -GlaxoSmithKline Outstanding Clinical Scholar Award, Lady Tata Memorial Trust International Award Fellowship, ISSNAF (Italian Scientists and Scholars in North America Foundation) Paola Campese Award for Research on leukemia and first place in UNDER40 in Hematology in 2019 from the Italian Society of Hematology. Her research modeling erythroleukemia was presented as Plenary Scientific presentation at the 60th ASH Annual Meeting and her recent large scale genomic analysis revising the taxonomy of myeloid disease was presented as Late Breaking Abstract presentation at the 61th ASH Annual Meeting.
Dr Christian Steidl (Canada)
Dr Steidl is the Research Director of the Centre for Lymphoid Cancer, Associate Vice President Research at BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He has expertise in clinical malignant hematology, molecular pathology, genomics and lymphoma biology. Dr Steidl’s translational research group focuses on the pathogenesis of B cell lymphomas, tumor microenvironment biology and applied genomics. He is most known for his discovery and characterization of novel gene mutations in Non-Hodgkin lymphomas and microenvironment-related biomarkers in Hodgkin lymphoma. Dr Steidl is a member of the Scientific Advisory Board of the Lymphoma Research Foundation, past chair of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia and Member of the Leukemia and Lymphoma Society of Canada Medical and Scientific Advisory Committee. He was inducted as a member of the Royal Society of Canada, College for New Scholars, Artists and Scientists in 2017, and won an Allen Distinguished Investigator award in 2018.
A/Prof Saar Gill (USA)
Saar Gill MD PhD is an Assistant Professor of Medicine at the Center for Cellular Immunotherapies at the Perelman School of Medicine, University of Pennsylvania. The goals of the Gill Laboratory are to produce effective and safe CAR T cells for the treatment of hematologic malignancies such as leukemia and lymphoma. Dr. Gill’s research interests include: Human T cell immunology, allogeneic transplanation-related correlative sciences including graft-versus-host disease, the tumor microenvironment, and primarily, adoptive cellular therapy for the treatment of malignancy.